“There is no mRNA manufacturing capacity in the world — this is a new technology,” [Moderna CEO Stéphane] Bancel added. “You cannot go hire people who know how to make mRNA. Those people don’t exist. And then even if all those things were available, whoever wants to do mRNA vaccines will have to, you know, buy the machine, invent the manufacturing process, invent creation processes and ethical processes, and then they will have to go run a clinical trial, get the data, get the product approved and scale manufacturing. This doesn’t happen in six or 12 or 18 months.”
Several officials involved in the U.S. coronavirus response said they worried the decision would damage their relationship with the drug industry, noting the Biden administration is relying on it not just to boost vaccine supply but also to devise additional coronavirus treatments and vaccines, particularly given the risk of variants.
“We’re all counting on pharma to come up with vaccine booster shots, and what happens when we try to get to the front of the line?” said one official, speaking on the condition of anonymity because they were not authorized to publicly comment.
Biden's support for Covid vaccine wavier got a lot of headlines. But it could take months, or longer, for agreement and years for countries to build up capacity.
The result: It's unlikely to boost global supply quickly
Story with @ddiamond/@JStein_WaPo https://t.co/yiqfB9bwDS
— Tyler Pager (@tylerpager) May 7, 2021